Research-based pharma companies have been stimulated by the development of the Access to Medicine Foundation’s Access to Medicine Index, which facilitates improved accessibility, availability, affordability, and acceptability of medicines to patients in need, specifically in low to middle-income countries.
Isabel Torres, global head for access to medicine at Japanese pharma major Takeda Pharmaceutical (TYO: 4502), tells The Pharma Letter about its Access to Medicine (AtM) strategy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze